JCR Pharmaceuticals Co., Ltd.

Tokyo Stock Exchange 4552.T

JCR Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -13.42 M

JCR Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities is USD -13.42 M for the year ending March 31, 2024, a -191.52% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

JCR Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 14.66 M, a 181.91% change year over year.
JCR Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -17.90 M, a -123.87% change year over year.
JCR Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 74.99 M, a 293.74% change year over year.
JCR Pharmaceuticals Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD 19.04 M, a 330.27% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Tokyo Stock Exchange: 4552.T

JCR Pharmaceuticals Co., Ltd.

CEO	Mr. Shin Ashida
IPO Date	Nov. 17, 2005
Location	Japan
Headquarters	3-19 Kasuga-cho
Employees	934
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Pharmaceuticals Vaccines

Description

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Key trends

Past 5 years